CELLS IN MATRIX

BRIEF DESCRIPTION & GOAL

Coordinated by Betalin Therapeutics, four consortium members addresses the constant need for more effective diabetes drugs. A reliable platform for the identification of lead compounds will reduce the failure rate in the development of new drugs. Human insulin-producing cells are reaggregated into pseudoislets using the Sphericalplate 5D. These small mini organs are part of a unique model that allows the development of an engineered micro pancreas (EMP). This offers new possibilities for acceleration and cost reduction in the development of diabetes drugs. The commercialization of EMPs includes direct end users such as academic institutions as well as the pharmaceutical industry.

The aim of the project is to develop an organ-derived 3D cell culture model that builds an engineered micro pancreas of human insulin-producing cells and provides a novel platform for diabetes R&D.

OUR ROLE

Kugelmeiers Ltd. has long-standing experience in the field of scaffold-free 3D cell culture and the production, handling and cultivation of (stem cell-based) spheroids. With the Sphericalplate 5D, the company has developed a translational platform for upscaling of standardized spheroids of any type and size allowing various scientific applications. Many years of professional involvement in the medical technology industry have resulted in a strong expertise in the areas of diabetes and islet transplantation, regulatory approvals of developed medical devices and cell products as well as in marketing strategies and global distribution. This provides ideal syngergies with Betalin Therapeutics as commercial leading partner for the development, market entry and commercialization of the EMP product.

Link project website

Project Partners